Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

ASCO coverage

Home/Tag:ASCO coverage
9 06, 2014

Pat’s 2014 ASCO Review

Tags: , , , |7 Comments

Disappointed with limited of myeloma related news trickling out of Chicago last week?  You shouldn't be. True, there wasn't a lot of new data presented at this year's American Society of Clinical Oncology (ASCO) meetings.  But some was significant.  And more will be available June 12th - 15th at the European Hematology Association (EHA) conference

4 06, 2014

TH-302 uses new pathway to shrink myeloma lesions

Tags: , |4 Comments

Here's an ASCO "sleeper."  Threshold Pharmaceutical's TH-302 is a classic example of throwing an unproven anticancer drug at the wall to see what sticks.  Fortunately, an early study shows TH-302 may zap multiple myeloma. Things must be progressing better than expected. When I reported on an ongoing TH-302 study last year at ASCO, I noted

30 05, 2013

ASCO Coverage begins tomorrow; with a twist!

Tags: , , |4 Comments

I'm excited to remind everyone that the American Society of Clinical Oncology (ASCO) meetings--the world's largest gathering of oncologist researchers, clinicians, pharmaceutical company teams and reporters--kicks-off shortly in Chicago.  Please don't run for cover!  Please don't allow your eyes to glaze over or turn-off your computers!  This year I promise to provide kinder, gentler and